Cell therapy
| RESOURCE | INDICATION | PRECLINICAL DISCOVERYIND | CLINICAL DEVELOPMENTBLA | FDA APPROVAL | ||||
|---|---|---|---|---|---|---|---|---|
| Drug Product | DISCOVERY | PRECLINICAL DEVELOPMENT | PHASE I | PHASE II | PHASE III | |||
Cord Blood RegeneCyte |
||||||||
|
Cord Blood RegeneCyte
|
80+ FDA approved indication | |||||||
| Post-Covid | ||||||||
| Acute Stroke | ||||||||
| Cerebral Palsy | ||||||||
| RegeneCyte is an allogeneic umbilical cord blood cellular biotherapy approved by the U.S. FDA, designed to treat over 80 indications, including 17 types of cancer (e.g., leukemia, multiple myeloma, neuroblastoma), 20 hematological disorders (e.g., thalassemia, congenital aplastic anemia, myelodysplastic syndromes), 26 immune-related conditions (e.g., severe combined immunodeficiency [SCID]), and 17 metabolic disorders (e.g., mucopolysaccharidosis, adrenoleukodystrophy). To date, RegeneCyte has been successfully applied in the treatment of over 2,300 patients worldwide. Beyond its approved indications, RegeneCyte is currently undergoing clinical trials for emerging applications, including long COVID syndrome, acute ischemic stroke, and cerebral palsy, further expanding its therapeutic potential. 80 Standard Diseases Treated by Cord Blood Transplant |
||||||||
| CB201(CB-NK) |
||||||||
| API | CB201(CB-NK) | Hematological Malignancies | ||||||